nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—CYP3A4—bone cancer	0.618	1	CbGaD
Enzalutamide—CYP2B6—Cisplatin—bone cancer	0.0568	0.22	CbGbCtD
Enzalutamide—CYP2B6—Doxorubicin—bone cancer	0.0381	0.147	CbGbCtD
Enzalutamide—ALB—Methotrexate—bone cancer	0.0362	0.14	CbGbCtD
Enzalutamide—CYP2C9—Cisplatin—bone cancer	0.03	0.116	CbGbCtD
Enzalutamide—ABCB1—Cisplatin—bone cancer	0.0291	0.113	CbGbCtD
Enzalutamide—ABCB1—Doxorubicin—bone cancer	0.0195	0.0754	CbGbCtD
Enzalutamide—ABCB1—Methotrexate—bone cancer	0.0189	0.0731	CbGbCtD
Enzalutamide—CYP2D6—Doxorubicin—bone cancer	0.0184	0.0711	CbGbCtD
Enzalutamide—CYP3A4—Doxorubicin—bone cancer	0.0117	0.0452	CbGbCtD
Enzalutamide—Bicalutamide—CYP3A4—bone cancer	0.00483	1	CrCbGaD
Enzalutamide—Lung infection—Methotrexate—bone cancer	0.00347	0.0714	CcSEcCtD
Enzalutamide—AR—Nuclear Receptors—NR1I2—bone cancer	0.00152	0.0218	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—FEV—bone cancer	0.00145	0.0208	CbGpPWpGaD
Enzalutamide—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00144	0.0207	CbGpPWpGaD
Enzalutamide—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00143	0.0205	CbGpPWpGaD
Enzalutamide—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00137	0.0198	CbGpPWpGaD
Enzalutamide—Cognitive disorder—Methotrexate—bone cancer	0.00132	0.0271	CcSEcCtD
Enzalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00128	0.0184	CbGpPWpGaD
Enzalutamide—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00126	0.0181	CbGpPWpGaD
Enzalutamide—Infection—Carboplatin—bone cancer	0.00126	0.0258	CcSEcCtD
Enzalutamide—AR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0012	0.0173	CbGpPWpGaD
Enzalutamide—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00119	0.017	CbGpPWpGaD
Enzalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00118	0.017	CbGpPWpGaD
Enzalutamide—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00118	0.0169	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00118	0.0169	CbGpPWpGaD
Enzalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00117	0.0168	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—FOLR1—bone cancer	0.00114	0.0164	CbGpPWpGaD
Enzalutamide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00112	0.0161	CbGpPWpGaD
Enzalutamide—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00107	0.0153	CbGpPWpGaD
Enzalutamide—Fracture—Methotrexate—bone cancer	0.000981	0.0202	CcSEcCtD
Enzalutamide—Multiple fractures—Methotrexate—bone cancer	0.000981	0.0202	CcSEcCtD
Enzalutamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000918	0.0132	CbGpPWpGaD
Enzalutamide—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000835	0.012	CbGpPWpGaD
Enzalutamide—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.00082	0.0118	CbGpPWpGaD
Enzalutamide—Amnesia—Cisplatin—bone cancer	0.000803	0.0165	CcSEcCtD
Enzalutamide—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000801	0.0115	CbGpPWpGaD
Enzalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000772	0.0111	CbGpPWpGaD
Enzalutamide—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000771	0.0111	CbGpPWpGaD
Enzalutamide—Laryngitis—Epirubicin—bone cancer	0.00074	0.0152	CcSEcCtD
Enzalutamide—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000731	0.0105	CbGpPWpGaD
Enzalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000726	0.0104	CbGpPWpGaD
Enzalutamide—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000715	0.0103	CbGpPWpGaD
Enzalutamide—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000694	0.00997	CbGpPWpGaD
Enzalutamide—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000689	0.0099	CbGpPWpGaD
Enzalutamide—Laryngitis—Doxorubicin—bone cancer	0.000685	0.0141	CcSEcCtD
Enzalutamide—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000681	0.00979	CbGpPWpGaD
Enzalutamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000677	0.00973	CbGpPWpGaD
Enzalutamide—Nasopharyngitis—Cisplatin—bone cancer	0.000674	0.0139	CcSEcCtD
Enzalutamide—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000667	0.00959	CbGpPWpGaD
Enzalutamide—Musculoskeletal stiffness—Methotrexate—bone cancer	0.000635	0.0131	CcSEcCtD
Enzalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000632	0.00909	CbGpPWpGaD
Enzalutamide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000619	0.0089	CbGpPWpGaD
Enzalutamide—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000619	0.00889	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—ZNF77—bone cancer	0.000613	0.00881	CbGpPWpGaD
Enzalutamide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000596	0.00856	CbGpPWpGaD
Enzalutamide—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00057	0.00819	CbGpPWpGaD
Enzalutamide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000565	0.00812	CbGpPWpGaD
Enzalutamide—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000563	0.00809	CbGpPWpGaD
Enzalutamide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000552	0.00794	CbGpPWpGaD
Enzalutamide—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00055	0.00791	CbGpPWpGaD
Enzalutamide—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000548	0.00788	CbGpPWpGaD
Enzalutamide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000543	0.00781	CbGpPWpGaD
Enzalutamide—Musculoskeletal pain—Epirubicin—bone cancer	0.00054	0.0111	CcSEcCtD
Enzalutamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000536	0.00771	CbGpPWpGaD
Enzalutamide—Urinary tract disorder—Cisplatin—bone cancer	0.000515	0.0106	CcSEcCtD
Enzalutamide—Connective tissue disorder—Cisplatin—bone cancer	0.000513	0.0105	CcSEcCtD
Enzalutamide—Urethral disorder—Cisplatin—bone cancer	0.000511	0.0105	CcSEcCtD
Enzalutamide—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000508	0.0073	CbGpPWpGaD
Enzalutamide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000504	0.00724	CbGpPWpGaD
Enzalutamide—Musculoskeletal pain—Doxorubicin—bone cancer	0.0005	0.0103	CcSEcCtD
Enzalutamide—Sepsis—Methotrexate—bone cancer	0.000495	0.0102	CcSEcCtD
Enzalutamide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000469	0.00674	CbGpPWpGaD
Enzalutamide—Sepsis—Epirubicin—bone cancer	0.000463	0.00951	CcSEcCtD
Enzalutamide—Sepsis—Doxorubicin—bone cancer	0.000428	0.0088	CcSEcCtD
Enzalutamide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000425	0.00611	CbGpPWpGaD
Enzalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000417	0.00599	CbGpPWpGaD
Enzalutamide—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000415	0.00597	CbGpPWpGaD
Enzalutamide—Hot flush—Epirubicin—bone cancer	0.000414	0.0085	CcSEcCtD
Enzalutamide—Menopausal symptoms—Epirubicin—bone cancer	0.00041	0.00843	CcSEcCtD
Enzalutamide—Leukopenia—Cisplatin—bone cancer	0.000406	0.00835	CcSEcCtD
Enzalutamide—AR—Notch-mediated HES/HEY network—RB1—bone cancer	0.000404	0.0058	CbGpPWpGaD
Enzalutamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000395	0.00568	CbGpPWpGaD
Enzalutamide—Convulsion—Cisplatin—bone cancer	0.000393	0.00808	CcSEcCtD
Enzalutamide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000388	0.00557	CbGpPWpGaD
Enzalutamide—Anxiety—Cisplatin—bone cancer	0.000385	0.00792	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000384	0.00789	CcSEcCtD
Enzalutamide—Hot flush—Doxorubicin—bone cancer	0.000383	0.00787	CcSEcCtD
Enzalutamide—Menopausal symptoms—Doxorubicin—bone cancer	0.00038	0.0078	CcSEcCtD
Enzalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000369	0.00531	CbGpPWpGaD
Enzalutamide—Infection—Cisplatin—bone cancer	0.000368	0.00756	CcSEcCtD
Enzalutamide—Nervous system disorder—Cisplatin—bone cancer	0.000363	0.00747	CcSEcCtD
Enzalutamide—Thrombocytopenia—Cisplatin—bone cancer	0.000363	0.00746	CcSEcCtD
Enzalutamide—Skin disorder—Cisplatin—bone cancer	0.00036	0.0074	CcSEcCtD
Enzalutamide—Dry skin—Epirubicin—bone cancer	0.000355	0.00729	CcSEcCtD
Enzalutamide—Nasopharyngitis—Epirubicin—bone cancer	0.000346	0.00711	CcSEcCtD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000346	0.00497	CbGpPWpGaD
Enzalutamide—Muscular weakness—Epirubicin—bone cancer	0.000342	0.00702	CcSEcCtD
Enzalutamide—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00034	0.00489	CbGpPWpGaD
Enzalutamide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000338	0.00694	CcSEcCtD
Enzalutamide—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000336	0.00483	CbGpPWpGaD
Enzalutamide—Neutropenia—Methotrexate—bone cancer	0.000334	0.00687	CcSEcCtD
Enzalutamide—Paraesthesia—Cisplatin—bone cancer	0.000333	0.00684	CcSEcCtD
Enzalutamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000333	0.00478	CbGpPWpGaD
Enzalutamide—Upper respiratory tract infection—Methotrexate—bone cancer	0.000332	0.00683	CcSEcCtD
Enzalutamide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000332	0.00477	CbGpPWpGaD
Enzalutamide—Dry skin—Doxorubicin—bone cancer	0.000328	0.00675	CcSEcCtD
Enzalutamide—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000328	0.00472	CbGpPWpGaD
Enzalutamide—Bronchitis—Epirubicin—bone cancer	0.000322	0.00661	CcSEcCtD
Enzalutamide—Pneumonia—Methotrexate—bone cancer	0.000321	0.00659	CcSEcCtD
Enzalutamide—Nasopharyngitis—Doxorubicin—bone cancer	0.00032	0.00658	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Cisplatin—bone cancer	0.00032	0.00657	CcSEcCtD
Enzalutamide—Infestation—Methotrexate—bone cancer	0.000319	0.00655	CcSEcCtD
Enzalutamide—Infestation NOS—Methotrexate—bone cancer	0.000319	0.00655	CcSEcCtD
Enzalutamide—Muscular weakness—Doxorubicin—bone cancer	0.000316	0.00649	CcSEcCtD
Enzalutamide—AR—FOXA1 transcription factor network—JUN—bone cancer	0.000315	0.00453	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—DHFR—bone cancer	0.000313	0.0045	CbGpPWpGaD
Enzalutamide—Neutropenia—Epirubicin—bone cancer	0.000313	0.00643	CcSEcCtD
Enzalutamide—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000313	0.00449	CbGpPWpGaD
Enzalutamide—Upper respiratory tract infection—Epirubicin—bone cancer	0.000311	0.00639	CcSEcCtD
Enzalutamide—Pollakiuria—Epirubicin—bone cancer	0.000309	0.00635	CcSEcCtD
Enzalutamide—Haematuria—Methotrexate—bone cancer	0.000304	0.00625	CcSEcCtD
Enzalutamide—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000302	0.00434	CbGpPWpGaD
Enzalutamide—Epistaxis—Methotrexate—bone cancer	0.000301	0.00618	CcSEcCtD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.0003	0.00432	CbGpPWpGaD
Enzalutamide—Pneumonia—Epirubicin—bone cancer	0.0003	0.00617	CcSEcCtD
Enzalutamide—Infestation—Epirubicin—bone cancer	0.000298	0.00613	CcSEcCtD
Enzalutamide—Infestation NOS—Epirubicin—bone cancer	0.000298	0.00613	CcSEcCtD
Enzalutamide—Bronchitis—Doxorubicin—bone cancer	0.000298	0.00612	CcSEcCtD
Enzalutamide—AR—Gene Expression—ZNF77—bone cancer	0.000295	0.00424	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000294	0.00423	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00029	0.00417	CbGpPWpGaD
Enzalutamide—Neutropenia—Doxorubicin—bone cancer	0.00029	0.00595	CcSEcCtD
Enzalutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000288	0.00414	CbGpPWpGaD
Enzalutamide—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000288	0.00591	CcSEcCtD
Enzalutamide—Pollakiuria—Doxorubicin—bone cancer	0.000286	0.00588	CcSEcCtD
Enzalutamide—Haematuria—Epirubicin—bone cancer	0.000285	0.00585	CcSEcCtD
Enzalutamide—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000284	0.00409	CbGpPWpGaD
Enzalutamide—Pharyngitis—Methotrexate—bone cancer	0.000284	0.00584	CcSEcCtD
Enzalutamide—Urinary tract disorder—Methotrexate—bone cancer	0.000283	0.00581	CcSEcCtD
Enzalutamide—Epistaxis—Epirubicin—bone cancer	0.000281	0.00578	CcSEcCtD
Enzalutamide—Urethral disorder—Methotrexate—bone cancer	0.000281	0.00577	CcSEcCtD
Enzalutamide—Sinusitis—Epirubicin—bone cancer	0.00028	0.00575	CcSEcCtD
Enzalutamide—Pneumonia—Doxorubicin—bone cancer	0.000278	0.00571	CcSEcCtD
Enzalutamide—Infestation—Doxorubicin—bone cancer	0.000276	0.00567	CcSEcCtD
Enzalutamide—Infestation NOS—Doxorubicin—bone cancer	0.000276	0.00567	CcSEcCtD
Enzalutamide—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000276	0.00397	CbGpPWpGaD
Enzalutamide—ALB—Platelet degranulation—SPARC—bone cancer	0.000275	0.00395	CbGpPWpGaD
Enzalutamide—AR—Regulation of Androgen receptor activity—JUN—bone cancer	0.000272	0.00391	CbGpPWpGaD
Enzalutamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00027	0.00388	CbGpPWpGaD
Enzalutamide—Rhinitis—Epirubicin—bone cancer	0.000269	0.00552	CcSEcCtD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000268	0.00385	CbGpPWpGaD
Enzalutamide—Hypoaesthesia—Epirubicin—bone cancer	0.000267	0.00548	CcSEcCtD
Enzalutamide—Asthenia—Cisplatin—bone cancer	0.000266	0.00546	CcSEcCtD
Enzalutamide—Pharyngitis—Epirubicin—bone cancer	0.000266	0.00546	CcSEcCtD
Enzalutamide—Urinary tract disorder—Epirubicin—bone cancer	0.000265	0.00544	CcSEcCtD
Enzalutamide—Oedema peripheral—Epirubicin—bone cancer	0.000264	0.00542	CcSEcCtD
Enzalutamide—Haematuria—Doxorubicin—bone cancer	0.000263	0.00541	CcSEcCtD
Enzalutamide—Connective tissue disorder—Epirubicin—bone cancer	0.000263	0.00541	CcSEcCtD
Enzalutamide—Urethral disorder—Epirubicin—bone cancer	0.000263	0.0054	CcSEcCtD
Enzalutamide—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000262	0.00376	CbGpPWpGaD
Enzalutamide—Epistaxis—Doxorubicin—bone cancer	0.00026	0.00535	CcSEcCtD
Enzalutamide—Angiopathy—Methotrexate—bone cancer	0.00026	0.00534	CcSEcCtD
Enzalutamide—Sinusitis—Doxorubicin—bone cancer	0.000259	0.00532	CcSEcCtD
Enzalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000257	0.0037	CbGpPWpGaD
Enzalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000254	0.00365	CbGpPWpGaD
Enzalutamide—Diarrhoea—Cisplatin—bone cancer	0.000254	0.00521	CcSEcCtD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000253	0.00364	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000252	0.00362	CbGpPWpGaD
Enzalutamide—Mental disorder—Methotrexate—bone cancer	0.000251	0.00515	CcSEcCtD
Enzalutamide—Rhinitis—Doxorubicin—bone cancer	0.000248	0.00511	CcSEcCtD
Enzalutamide—Hypoaesthesia—Doxorubicin—bone cancer	0.000247	0.00507	CcSEcCtD
Enzalutamide—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000246	0.00354	CbGpPWpGaD
Enzalutamide—Pharyngitis—Doxorubicin—bone cancer	0.000246	0.00505	CcSEcCtD
Enzalutamide—Urinary tract disorder—Doxorubicin—bone cancer	0.000245	0.00503	CcSEcCtD
Enzalutamide—Oedema peripheral—Doxorubicin—bone cancer	0.000244	0.00502	CcSEcCtD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000244	0.00351	CbGpPWpGaD
Enzalutamide—Connective tissue disorder—Doxorubicin—bone cancer	0.000244	0.005	CcSEcCtD
Enzalutamide—Angiopathy—Epirubicin—bone cancer	0.000243	0.00499	CcSEcCtD
Enzalutamide—Urethral disorder—Doxorubicin—bone cancer	0.000243	0.00499	CcSEcCtD
Enzalutamide—AR—Androgen receptor signaling pathway—RB1—bone cancer	0.000242	0.00348	CbGpPWpGaD
Enzalutamide—Back pain—Methotrexate—bone cancer	0.000241	0.00495	CcSEcCtD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000241	0.00346	CbGpPWpGaD
Enzalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000237	0.0034	CbGpPWpGaD
Enzalutamide—Mental disorder—Epirubicin—bone cancer	0.000235	0.00482	CcSEcCtD
Enzalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000235	0.00337	CbGpPWpGaD
Enzalutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000234	0.00336	CbGpPWpGaD
Enzalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000233	0.00336	CbGpPWpGaD
Enzalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000231	0.00333	CbGpPWpGaD
Enzalutamide—Back pain—Epirubicin—bone cancer	0.000226	0.00463	CcSEcCtD
Enzalutamide—Angiopathy—Doxorubicin—bone cancer	0.000225	0.00462	CcSEcCtD
Enzalutamide—Vertigo—Methotrexate—bone cancer	0.000224	0.0046	CcSEcCtD
Enzalutamide—Leukopenia—Methotrexate—bone cancer	0.000223	0.00458	CcSEcCtD
Enzalutamide—Mental disorder—Doxorubicin—bone cancer	0.000217	0.00446	CcSEcCtD
Enzalutamide—Convulsion—Methotrexate—bone cancer	0.000216	0.00444	CcSEcCtD
Enzalutamide—Arthralgia—Methotrexate—bone cancer	0.000212	0.00436	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000211	0.00433	CcSEcCtD
Enzalutamide—Vertigo—Epirubicin—bone cancer	0.00021	0.0043	CcSEcCtD
Enzalutamide—Leukopenia—Epirubicin—bone cancer	0.000209	0.00429	CcSEcCtD
Enzalutamide—Back pain—Doxorubicin—bone cancer	0.000209	0.00429	CcSEcCtD
Enzalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000209	0.003	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—NR1I2—bone cancer	0.000207	0.00298	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—MDM2—bone cancer	0.000207	0.00297	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000204	0.00293	CbGpPWpGaD
Enzalutamide—Convulsion—Epirubicin—bone cancer	0.000202	0.00415	CcSEcCtD
Enzalutamide—Infection—Methotrexate—bone cancer	0.000202	0.00415	CcSEcCtD
Enzalutamide—Hypertension—Epirubicin—bone cancer	0.000201	0.00414	CcSEcCtD
Enzalutamide—Nervous system disorder—Methotrexate—bone cancer	0.000199	0.0041	CcSEcCtD
Enzalutamide—Thrombocytopenia—Methotrexate—bone cancer	0.000199	0.00409	CcSEcCtD
Enzalutamide—Arthralgia—Epirubicin—bone cancer	0.000199	0.00408	CcSEcCtD
Enzalutamide—Anxiety—Epirubicin—bone cancer	0.000198	0.00406	CcSEcCtD
Enzalutamide—Skin disorder—Methotrexate—bone cancer	0.000198	0.00406	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000197	0.00405	CcSEcCtD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.000195	0.00281	CbGpPWpGaD
Enzalutamide—Vertigo—Doxorubicin—bone cancer	0.000194	0.00398	CcSEcCtD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000194	0.00278	CbGpPWpGaD
Enzalutamide—Leukopenia—Doxorubicin—bone cancer	0.000193	0.00397	CcSEcCtD
Enzalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000192	0.00276	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.00019	0.00273	CbGpPWpGaD
Enzalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00019	0.00273	CbGpPWpGaD
Enzalutamide—Infection—Epirubicin—bone cancer	0.000189	0.00388	CcSEcCtD
Enzalutamide—Convulsion—Doxorubicin—bone cancer	0.000187	0.00384	CcSEcCtD
Enzalutamide—Nervous system disorder—Epirubicin—bone cancer	0.000187	0.00383	CcSEcCtD
Enzalutamide—Thrombocytopenia—Epirubicin—bone cancer	0.000186	0.00383	CcSEcCtD
Enzalutamide—Hypertension—Doxorubicin—bone cancer	0.000186	0.00383	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000185	0.00381	CcSEcCtD
Enzalutamide—Skin disorder—Epirubicin—bone cancer	0.000185	0.0038	CcSEcCtD
Enzalutamide—Insomnia—Methotrexate—bone cancer	0.000184	0.00378	CcSEcCtD
Enzalutamide—Arthralgia—Doxorubicin—bone cancer	0.000184	0.00377	CcSEcCtD
Enzalutamide—Anxiety—Doxorubicin—bone cancer	0.000183	0.00376	CcSEcCtD
Enzalutamide—Paraesthesia—Methotrexate—bone cancer	0.000183	0.00375	CcSEcCtD
Enzalutamide—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000183	0.00262	CbGpPWpGaD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000182	0.00375	CcSEcCtD
Enzalutamide—AR—Androgen receptor signaling pathway—JUN—bone cancer	0.00018	0.00258	CbGpPWpGaD
Enzalutamide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000176	0.00361	CcSEcCtD
Enzalutamide—Fatigue—Methotrexate—bone cancer	0.000175	0.0036	CcSEcCtD
Enzalutamide—Infection—Doxorubicin—bone cancer	0.000175	0.00359	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000173	0.00356	CcSEcCtD
Enzalutamide—Nervous system disorder—Doxorubicin—bone cancer	0.000173	0.00355	CcSEcCtD
Enzalutamide—Thrombocytopenia—Doxorubicin—bone cancer	0.000172	0.00354	CcSEcCtD
Enzalutamide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000172	0.00248	CbGpPWpGaD
Enzalutamide—Insomnia—Epirubicin—bone cancer	0.000172	0.00354	CcSEcCtD
Enzalutamide—Skin disorder—Doxorubicin—bone cancer	0.000171	0.00351	CcSEcCtD
Enzalutamide—Paraesthesia—Epirubicin—bone cancer	0.000171	0.00351	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000164	0.00338	CcSEcCtD
Enzalutamide—Fatigue—Epirubicin—bone cancer	0.000164	0.00337	CcSEcCtD
Enzalutamide—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000161	0.00232	CbGpPWpGaD
Enzalutamide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00016	0.0033	CcSEcCtD
Enzalutamide—Insomnia—Doxorubicin—bone cancer	0.000159	0.00327	CcSEcCtD
Enzalutamide—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000159	0.00228	CbGpPWpGaD
Enzalutamide—Paraesthesia—Doxorubicin—bone cancer	0.000158	0.00325	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000152	0.00312	CcSEcCtD
Enzalutamide—Fatigue—Doxorubicin—bone cancer	0.000152	0.00312	CcSEcCtD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000151	0.00217	CbGpPWpGaD
Enzalutamide—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000148	0.00212	CbGpPWpGaD
Enzalutamide—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000147	0.00211	CbGpPWpGaD
Enzalutamide—Asthenia—Methotrexate—bone cancer	0.000146	0.003	CcSEcCtD
Enzalutamide—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000145	0.00208	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—FUS—bone cancer	0.000144	0.00207	CbGpPWpGaD
Enzalutamide—Pruritus—Methotrexate—bone cancer	0.000144	0.00296	CcSEcCtD
Enzalutamide—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000143	0.00206	CbGpPWpGaD
Enzalutamide—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000141	0.00203	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—EGFR—bone cancer	0.000141	0.00203	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000141	0.00203	CbGpPWpGaD
Enzalutamide—Diarrhoea—Methotrexate—bone cancer	0.000139	0.00286	CcSEcCtD
Enzalutamide—Asthenia—Epirubicin—bone cancer	0.000137	0.00281	CcSEcCtD
Enzalutamide—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000135	0.00194	CbGpPWpGaD
Enzalutamide—Pruritus—Epirubicin—bone cancer	0.000135	0.00277	CcSEcCtD
Enzalutamide—Dizziness—Methotrexate—bone cancer	0.000134	0.00276	CcSEcCtD
Enzalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000132	0.0019	CbGpPWpGaD
Enzalutamide—Diarrhoea—Epirubicin—bone cancer	0.00013	0.00268	CcSEcCtD
Enzalutamide—Headache—Methotrexate—bone cancer	0.000127	0.00262	CcSEcCtD
Enzalutamide—Asthenia—Doxorubicin—bone cancer	0.000126	0.0026	CcSEcCtD
Enzalutamide—Dizziness—Epirubicin—bone cancer	0.000126	0.00259	CcSEcCtD
Enzalutamide—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000125	0.0018	CbGpPWpGaD
Enzalutamide—Pruritus—Doxorubicin—bone cancer	0.000125	0.00256	CcSEcCtD
Enzalutamide—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000124	0.00178	CbGpPWpGaD
Enzalutamide—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000124	0.00178	CbGpPWpGaD
Enzalutamide—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000123	0.00176	CbGpPWpGaD
Enzalutamide—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000122	0.00176	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000122	0.00175	CbGpPWpGaD
Enzalutamide—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000121	0.00174	CbGpPWpGaD
Enzalutamide—Diarrhoea—Doxorubicin—bone cancer	0.00012	0.00248	CcSEcCtD
Enzalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.00012	0.00173	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00012	0.00172	CbGpPWpGaD
Enzalutamide—Headache—Epirubicin—bone cancer	0.000119	0.00245	CcSEcCtD
Enzalutamide—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000118	0.00169	CbGpPWpGaD
Enzalutamide—Dizziness—Doxorubicin—bone cancer	0.000116	0.00239	CcSEcCtD
Enzalutamide—AR—SIDS Susceptibility Pathways—JUN—bone cancer	0.000115	0.00165	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000112	0.00161	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000111	0.0016	CbGpPWpGaD
Enzalutamide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000111	0.00159	CbGpPWpGaD
Enzalutamide—Headache—Doxorubicin—bone cancer	0.00011	0.00227	CcSEcCtD
Enzalutamide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000109	0.00157	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000109	0.00157	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000108	0.00155	CbGpPWpGaD
Enzalutamide—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.000106	0.00153	CbGpPWpGaD
Enzalutamide—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000105	0.0015	CbGpPWpGaD
Enzalutamide—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000102	0.00146	CbGpPWpGaD
Enzalutamide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000101	0.00145	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000101	0.00145	CbGpPWpGaD
Enzalutamide—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.0001	0.00144	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—NR1I2—bone cancer	9.99e-05	0.00144	CbGpPWpGaD
Enzalutamide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	9.96e-05	0.00143	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.94e-05	0.00143	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.81e-05	0.00141	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	9.75e-05	0.0014	CbGpPWpGaD
Enzalutamide—CYP2C19—Biological oxidations—GSTP1—bone cancer	9.47e-05	0.00136	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.46e-05	0.00136	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	9.35e-05	0.00134	CbGpPWpGaD
Enzalutamide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	9.34e-05	0.00134	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	9.29e-05	0.00134	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	9.25e-05	0.00133	CbGpPWpGaD
Enzalutamide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.79e-05	0.00126	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—NDUFA12—bone cancer	8.79e-05	0.00126	CbGpPWpGaD
Enzalutamide—CYP2D6—Biological oxidations—GSTP1—bone cancer	8.71e-05	0.00125	CbGpPWpGaD
Enzalutamide—CYP2C9—Biological oxidations—GSTP1—bone cancer	8.64e-05	0.00124	CbGpPWpGaD
Enzalutamide—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	8.59e-05	0.00124	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—NDUFA12—bone cancer	8.59e-05	0.00123	CbGpPWpGaD
Enzalutamide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	8.52e-05	0.00122	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.31e-05	0.00119	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.29e-05	0.00119	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.17e-05	0.00117	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	7.76e-05	0.00112	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	7.66e-05	0.0011	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NDUFA12—bone cancer	7.44e-05	0.00107	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NDUFA12—bone cancer	7.4e-05	0.00106	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—EIF2S1—bone cancer	7.38e-05	0.00106	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—NT5C3A—bone cancer	7.28e-05	0.00105	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.16e-05	0.00103	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—NT5C3A—bone cancer	7.12e-05	0.00102	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—TP53—bone cancer	7e-05	0.00101	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NDUFA12—bone cancer	6.64e-05	0.000954	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NDUFA12—bone cancer	6.48e-05	0.000931	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	6.43e-05	0.000925	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—EZH2—bone cancer	6.41e-05	0.000921	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—SPARC—bone cancer	6.28e-05	0.000902	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.16e-05	0.000886	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NT5C3A—bone cancer	6.16e-05	0.000886	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NT5C3A—bone cancer	6.13e-05	0.000881	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NDUFA12—bone cancer	6.11e-05	0.000878	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NDUFA12—bone cancer	6.05e-05	0.00087	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—GNA11—bone cancer	5.74e-05	0.000825	CbGpPWpGaD
Enzalutamide—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.7e-05	0.000819	CbGpPWpGaD
Enzalutamide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.62e-05	0.000808	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NT5C3A—bone cancer	5.5e-05	0.000791	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NT5C3A—bone cancer	5.37e-05	0.000772	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IL3—bone cancer	5.2e-05	0.000748	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NT5C3A—bone cancer	5.06e-05	0.000727	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NT5C3A—bone cancer	5.02e-05	0.000721	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.57e-05	0.000657	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.41e-05	0.000633	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NDUFA12—bone cancer	3.99e-05	0.000574	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.97e-05	0.000571	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PLAU—bone cancer	3.41e-05	0.000491	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NT5C3A—bone cancer	3.31e-05	0.000475	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ENO2—bone cancer	3.19e-05	0.000458	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.12e-05	0.000449	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ENO2—bone cancer	3.12e-05	0.000448	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—DHFR—bone cancer	2.96e-05	0.000425	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—DHFR—bone cancer	2.89e-05	0.000416	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GNA11—bone cancer	2.77e-05	0.000397	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GNA11—bone cancer	2.7e-05	0.000388	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ENO2—bone cancer	2.7e-05	0.000388	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—ENO2—bone cancer	2.68e-05	0.000386	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.62e-05	0.000377	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CYP3A4—bone cancer	2.51e-05	0.00036	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—DHFR—bone cancer	2.5e-05	0.00036	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—DHFR—bone cancer	2.49e-05	0.000358	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CYP3A4—bone cancer	2.45e-05	0.000352	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ENO2—bone cancer	2.41e-05	0.000346	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—ENO2—bone cancer	2.35e-05	0.000338	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GNA11—bone cancer	2.34e-05	0.000336	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GNA11—bone cancer	2.33e-05	0.000335	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—DHFR—bone cancer	2.24e-05	0.000321	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ENO2—bone cancer	2.22e-05	0.000319	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ENO2—bone cancer	2.2e-05	0.000316	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—DHFR—bone cancer	2.18e-05	0.000314	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GSTP1—bone cancer	2.14e-05	0.000308	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CYP3A4—bone cancer	2.12e-05	0.000305	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.11e-05	0.000303	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CYP3A4—bone cancer	2.11e-05	0.000303	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.1e-05	0.000302	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GSTP1—bone cancer	2.1e-05	0.000301	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GNA11—bone cancer	2.09e-05	0.0003	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—DHFR—bone cancer	2.06e-05	0.000296	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GNA11—bone cancer	2.04e-05	0.000293	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—DHFR—bone cancer	2.04e-05	0.000293	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GNA11—bone cancer	1.92e-05	0.000276	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GNA11—bone cancer	1.91e-05	0.000274	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CYP3A4—bone cancer	1.89e-05	0.000272	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.88e-05	0.000271	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CYP3A4—bone cancer	1.85e-05	0.000266	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GSTP1—bone cancer	1.82e-05	0.000261	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GSTP1—bone cancer	1.8e-05	0.000259	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CYP3A4—bone cancer	1.74e-05	0.00025	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CYP3A4—bone cancer	1.73e-05	0.000248	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.72e-05	0.000247	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GSTP1—bone cancer	1.62e-05	0.000233	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GSTP1—bone cancer	1.58e-05	0.000227	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GSTP1—bone cancer	1.49e-05	0.000214	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GSTP1—bone cancer	1.48e-05	0.000212	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ENO2—bone cancer	1.45e-05	0.000208	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TP53—bone cancer	1.37e-05	0.000197	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—DHFR—bone cancer	1.34e-05	0.000193	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GNA11—bone cancer	1.26e-05	0.000181	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PTGS2—bone cancer	1.11e-05	0.00016	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PTGS2—bone cancer	1.09e-05	0.000156	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GSTP1—bone cancer	9.74e-06	0.00014	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PTGS2—bone cancer	9.4e-06	0.000135	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PTGS2—bone cancer	9.35e-06	0.000134	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PTGS2—bone cancer	8.39e-06	0.000121	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PTGS2—bone cancer	8.19e-06	0.000118	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PTGS2—bone cancer	7.72e-06	0.000111	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PTGS2—bone cancer	7.65e-06	0.00011	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PTGS2—bone cancer	5.05e-06	7.25e-05	CbGpPWpGaD
